A venture capital firm based Switzerland raised a new fund in 2019.  The firm generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 5 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe, with a core focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, medtech etc.. The firm focuses on companies developing biotech platforms, research tools and digital health startups. The firm will not invest in pure drug development companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, antibody development platforms and a technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in Austria manages a total of EUR 50 million in capital, and invests in seed and early stage opportunities in Austria. The firm initially invests up to EUR 1 million, with further capital reserved for potential follow-on rounds.

The firm will consider investing in any area of life science technology, including biotech, medical devices, diagnostics, and also agtech and environmental biotech. The firm is open to investing in early-stage companies that have not yet commenced human clinical trials; however, the firm will only invest in companies that have a working prototype or animal data for their product. While the firm will consider any technology or indication area, the firm generally prefers not to invest in health apps, or in fields such as oncology that incur high costs for clinical development.

The firm focuses on investing in their local area close to Vienna. The firm is open to being a lead investor but prefers not to be the sole investor in a round; the firm syndicates with other VCs and other sources of capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established Healthcare focused fund with offices in USA, Europe, and China, is broadly focused in Life Sciences with strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, and would like to lead investments and play active roles in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, and ophthalmology related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all opportunities within the early stage, however diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies that they have invested in. Outside of the board requirement, the firm is looking for strong management teams that demonstrate the capability to move their technology forwards.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An international firm conducts global business development and licensing searches in all stages of clinical diagnostics research and development, regardless of the technology involved. The firm employs a variety of deal structures including IP rights in- and out- licensing, product or technology co-development, and M&A.

The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity investment firm seeks early stage companies to form and establish, as well as investing to bridge the gap between late stage companies in Israel and companies with sales activity in the U.S. and Europe (“platforms”). For early-stage companies, the firm typically invests from a few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.

The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. The firm may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in diabetes, obesity, heart failure, structural heart, pulmonary hypertension, currently looking at neurology and urology, and is open to new areas of focus. For late-stage/platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.

For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm was founded in 2017 and has multiple offices in Europe. The firm makes venture investments across the life science sector from a €100 million fund.  The firm invests throughout Europe, with a focus on the Nordic region and Western Europe; initial investments are typically €4-6 million. The firm prefers to act as a lead investor, but may consider following on as part of a strong syndicate.

The firm invests across the life science sector, including therapeutics, devices and diagnostics.  The firm only invests in products that are subject to regulation.  The firm will consider any indication or modality. The firm prefers to invest in assets that are at least ready to go into clinical trials.

The firm focuses on assets that they consider to have below the average risk level of their peer group.  The firm prefers to lead investments, particularly in its home region, and performs their own due diligence even in cases in which they act as a co-investor.  While the firm does not exclude any areas of opportunity, there is a focus on de-risked assets and areas in which the execution and regulatory risk for the asset is reduced.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private wealth investment firm based in Europe focuses on investing in digital health, devices and diagnostics technologies. Though an early investor, the firm looks for companies that have some proof of concept data. The firm primarily invests in companies within the country where the firm is based, but will consider investments in North America, all of Europe and Israel. The firm generally looks to invest between 100K-2M EUR in their portfolio companies.

The firm will invest in digital health as well as diagnostics and devices as well as regenerative medicine technologies. For diagnostics and devices, the firm prefers companies with a digital component. In addition, the firm prefers devices without complex regulatory requirements. The firm is agnostic with regards to indication.

The firm is willing to lead or co-invest, although they are most likely to lead if investing in Hungary. Generally, the firm prefers to have a board or an observer seat after investing. Within the life sciences, the firm prefers to invest in teams with industry experience, especially for companies located outside of the country where the firm is based.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.